Sankala Group’s VanEck Biotech ETF BBH Stock Holding History

Sankala Group’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$12.3K	Sell	67 -19	-22%	-$3.66K	0.01%	352
2025 Q4	$17K	Buy	+86	New	+$15.9K	0.01%	329

Other funds holding BBH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

MIM

Miller Investment Management West Conshohocken, Pennsylvania $1.01B AUM 13.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

CCA

Conservest Capital Advisors Wynnewood, Pennsylvania $1.26B AUM 24.75% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BFG

Bleakley Financial Group Fairfield, New Jersey $7.85B AUM 31.48% 1-Year Est. Return

Sankala Group's BBH Position: Q1 2026 in Review

Sankala Group reduced its VanEck Biotech ETF (BBH) stake by 22% in Q1 2026, selling an estimated $3.66K and leaving 67 shares worth $12.3K. The position accounts for 0.01% of the portfolio, ranked #352.

Sankala Group first reported a position in BBH in Q4 2025 and has held it in 2 quarters since. The position peaked at $17K in Q4 2025. 112 funds tracked by Wall St. Rank hold BBH as of Q1 2026.

Sankala Group held 67 shares of VanEck Biotech ETF worth $12.3K as of Q1 2026.
Sankala Group sold 19 VanEck Biotech ETF shares in Q1 2026, an estimated $3.66K.
VanEck Biotech ETF made up 0.01% of Sankala Group's portfolio in Q1 2026, its #352 holding.
Sankala Group first reported a position in VanEck Biotech ETF in Q4 2025 and has held it in 2 quarters since.
Sankala Group's VanEck Biotech ETF position peaked at $17K in Q4 2025.
112 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q1 2026.

Based on Sankala Group's 13F filing for Q1 2026, filed 31 Mar 2026.